Sleep

In an interview Adrian Quartel, MD, discusses the next steps for evaluating KP1077 in idiopathic hypersomnia after the phase 2 study.

A study found individuals with type 2 diabetes who received less than 7 hours of sleep had 2.6 increased odds of microvascular disease.

Younger adults (aged 20 – 40 years) with OSA were 3 times more likely to experience any type of CVD event than those without OSA.

This Month in Review spotlights interviews conducted at SLEEP 2024 and a recent FDA approval.

FDA approves pitolisant for excessive daytime sleepiness and cataplexy in pediatric patients aged ≥ 6 years with narcolepsy.

Tirzepatide reduces OSA severity by 30 events/hour and achieves remission in up to 51% of patients with obesity, per SURMOUNT-OSA study results from Eli Lilly and Company.

At SLEEP 2024, Hartung discussed FloraWorks’ study finding patients on CBN had greater improvements in sleep quality than melatonin, but the difference was not significant.

Grandner highlights the importance of focusing on insomnia treatment for sleep-related anxiety—not anxiety treatment.

During SLEEP 2024, Judite Blanc, PhD, discussed her team’s ongoing study assessing whether an education VR program improves maternal stress and sleep among women of color.

At SLEEP 2024, Broussard told HCPLive about how eating time restriction can serve as another as another dietary tool for people who are unsuccessful with other strategies.

Broussard discussed the importance of eating during the day at SLEEP 2024.

In an interview at SLEEP 2024, Brager talked about the benefits of exercise on cardiovascular health and sleep.

Parthasarathy discussed next steps for research on the relationship between sleep disturbances and immunity in an interview with HCPLive at SLEEP 2024.

Parthasarathy told HCPLive women have a weaker immune response to COVID-19 than men.

In an interview with HCPLive, Parthasarathy discussed the relationship between sleep disturbances and immune function.